Key result
Albuminuria with preserved eGFR is linked to ~86% higher odds of prevalent CVD.
Why the study?
Albuminuria is a marker of kidney damage and cardiovascular risk that routine creatinine-based eGFR assessment does not detect. The study estimated the prevalence of albuminuria with preserved eGFR among U.S. adults and its association with prevalent CVD.
Cross-Sectional (n=5,282)
Yes
Albuminuria with preserved eGFR affects 7.8% of U.S. adults and is independently associated with nearly double the odds of prevalent cardiovascular disease, yet over a third of these individuals lack traditional diagnoses that would typically prompt urine albumin screening.
Answers are grounded in this paper and cite their sources.
May warrant UACR screening beyond traditional risks in preserved eGFR; extends cross-sectional associations but leaves causal and outcome benefits open.
Background: Albuminuria is a marker of kidney damage and cardiovascular risk, but routine creatinine-based assessment of estimated glomerular filtration rate (eGFR) does not detect it. We estimated how common albuminuria with preserved eGFR is among U.S. adults and examined its association with prevalent cardiovascular disease (CVD). Materials and methods: We analyzed 5,282 nonpregnant adults aged ≥20 years from the National Health and Nutrition Examination Survey, August 2021-August 2023. Participants were classified into four phenotypes by eGFR (2021 race-free CKD-EPI creatinine equation; cut point 60 mL/min/1.73 m²) and spot urine albumin-to-creatinine ratio (UACR; cut point 30 mg/g). Prevalent CVD was a self-reported diagnosis of heart failure, coronary heart disease, angina, myocardial infarction, or stroke. Associations were estimated with survey-weighted logistic regression, and the main estimates were independently reproduced in a second statistical software package. Secondary analyses estimated the share of affected adults with no diagnosed hypertension, diabetes, kidney disease, or CVD and the change in predicted 10-year total CVD risk when UACR was added to the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations. Results: Albuminuria with preserved eGFR was present in 7.8% of U.S. adults (95% confidence interval (CI): 6.9-8.7), or about 17.4 million people, and accounted for 79.1% of all adults with albuminuria. CVD prevalence was 22.2% in this group versus 6.4% in adults without kidney markers (adjusted odds ratio (OR): 1.86; 95% CI: 1.23-2.81). A simplified model with fewer parameters gave a similar result (OR: 1.87; 95% CI: 1.24-2.82). The odds of CVD did not differ significantly from those of adults with reduced eGFR without albuminuria (OR: 1.11; 95% CI: 0.72-1.72) and rose with albuminuria severity (OR: 1.13 per doubling of UACR). Among adults with albuminuria and preserved eGFR, 35.6% reported no diagnosis of hypertension, diabetes, kidney disease, or CVD, and only 3.2% had been told they had kidney disease. Adding UACR to PREVENT raised their mean predicted 10-year total CVD risk from 9.9% to 12.7% and moved 25.2% into a higher risk category. Conclusions: About one in 13 U.S. adults has albuminuria with preserved eGFR. This phenotype was associated with prevalent CVD independently of traditional risk factors, and many affected adults had no diagnosis that would usually prompt urine albumin testing. Prospective studies should test whether wider UACR testing improves cardiovascular prevention.
No takes yet. Share an insight, caveat, or question.
Ahammed et al. (2026) conducted a cross-sectional in Albuminuria with preserved estimated glomerular filtration rate and prevalent cardiovascular disease (n=5,282). Albuminuria with preserved eGFR (eGFR ≥60 mL/min/1.73 m² and UACR ≥30 mg/g) vs. No kidney markers (eGFR ≥60 mL/min/1.73 m² and UACR <30 mg/g) was evaluated on Prevalent cardiovascular disease (self-reported heart failure, coronary heart disease, angina, myocardial infarction, or stroke) (OR 1.86, 95% CI 1.23-2.81, p=0.006). Albuminuria with preserved eGFR was associated with higher odds of prevalent cardiovascular disease compared with no kidney markers.
Synapse has enriched 10 related papers. Consider them for comparative context: